Massive Bio

Handing over your medical records isn't a small step, and we don't treat it like one.

We ask for them because it's the only way to find trials that actually match your diagnosis, not a generic list. Your information is protected at every step: used only to evaluate eligibility, never sold, never shared beyond your care.

You're trusting us with something personal. We don't take that lightly.

Questions? We're here: https://massivebio.com/explore-clinical-trials/?utm_source=facebook&utm_medium=organic&utm_campaign=medical_records_trust

Reaching out about a clinical trial can feel like stepping into the unknown. It doesn't have to.

Here's exactly what happens after you contact us, step by step:

1️⃣ You tell us a little about your diagnosis and give your consent to move forward
2️⃣ We request your medical records and review your case for trials that actually fit
3️⃣ We match you with real options and stay with you through the next steps

No confusing forms. No jargon. No guesswork.

Ready to see what's out there for you? Link in bio to get started.

Leukemia, lymphoma, and myeloma aren't the same journey; they start differently, spread differently, and get treated differently.

Swipe through to see what actually sets them apart, and know that a clinical trial may be worth exploring at any stage, not just as a last resort.

https://massivebio.com/explore-clinical-trials/?utm_source=organic&utm_medium=facebook&utm_campaign=blood_cancer_awareness_month

Massive Bio has been named an OpenAI Select Partner within the OpenAI Partner Network.

This status builds on our continued work with OpenAI to bring GPT‑5.6 and ChatGPT Work into governed, oncology-specific AI workflows, helping healthcare and life sciences organizations move from promising pilots to measurable, production-scale impact in clinical research.

Read the full press release here: https://www.businesswire.com/news/home/20260805332425/en/Massive-Bio-Named-an-OpenAI-Select-Partner

Massive Bio has made its inaugural strategic investment in another AI company: Rivvi AI, Inc., an agentic AI infrastructure company for healthcare and life sciences.

The investment connects Massive Bio's prospectively validated oncology intelligence with Rivvi's agentic AI layer for healthcare, so patients can move from identification to informed action faster and with the right human support along the way.

Our Co-Founder and CEO Selin Kurnaz, our Chief Medical AI Officer Arturo Loaiza-Bonilla, and our Co-Founder, CTO & COO Çağatay Çulcuoğlu shared their perspectives on the announcement, alongside Rivvi Co-Founder and CEO Nathan Hayman.

Read the full press release here: https://www.businesswire.com/news/home/20260804887267/en/Massive-Bio-Makes-Inaugural-Strategic-Investment-in-Rivvi-to-Build-an-End-to-End-AI-Engagement-Infrastructure-for-Healthcare

Massive Bio and Healthcare have announced a national collaboration to transform cancer patient access, pairing Massive Bio's AI-driven clinical trial matching and patient navigation with QC Healthcare's nationwide telehealth and acute-care platforms.

The goal: give cancer patients rapid, coordinated access to care without ever stepping outside the trials that could save their lives, while keeping trial matching completely free to patients.

Read the full press release here: https://www.businesswire.com/news/home/20260729730523/en/Massive-Bio-and-QC-Healthcare-Announce-National-Collaboration-to-Transform-Cancer-Patient-Access

Massive Bio and GELL, the Latin American Study Group on Lymphoproliferative Disorders, have announced a strategic partnership to advance clinical research, physician education, and AI adoption across Latin America and the United States.

The collaboration brings together GELL's network of investigators and academic institutions in more than 20 countries with Massive Bio's AI-driven clinical trial matching platform, expanding scientific exchange and patient access to precision oncology.

Read the full announcement: https://www.businesswire.com/news/home/20260727304237/en/Massive-Bio-and-GELL-Announce-Strategic-Partnership-to-Advance-Research-Medical-Education-and-Artificial-Intelligence-Across-Latin-America-and-the-United-States

Grupo de Estudio Latinoamericano de Linfoproliferativos GELL

Massive Bio has announced a new partnership with FOMAT, the largest Embedded Research Organization in the United States, to expand AI-powered patient prescreening for oncology clinical trials.

The collaboration brings our AI platform into FOMAT's network of 40+ investigator sites across six states, helping identify eligible cancer patients earlier and reducing delays between diagnosis and trial access. It's launching as a pilot, with a broader rollout planned based on results.

"Prescreening has historically been manual, slow, and inconsistent," said Arturo Loaiza-Bonilla, MD, Co-Founder and Chief Medical AI Officer of Massive Bio. "Embedding AI into FOMAT's community-based sites means we can bring speed and precision to that step without disrupting the physician relationships that make FOMAT's model work."

Read more: https://www.businesswire.com/news/home/20260720835336/en/Massive-Bio-Partners-With-FOMAT-to-Expand-Cancer-Patient-Prescreening-for-Clinical-Trial-Access?utm_source=facebook&utm_medium=organic&utm_campaign=fomat-partnership

Clinical trials are transforming cancer care. ACS ACTS is a free program powered by unique matching technology, in collaboration with Massive Bio, to connect patients with personalized treatment options for any cancer type, while also assisting with housing, transportation, and other health-related needs.

Learn more about ACS ACTS: cancer.org/acts